Patents by Inventor Esa T. Jarvi

Esa T. Jarvi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation of normorphinans
    Patent number: 9127009
    Abstract: The present invention provides processes for preparing normorphinans from N-substituted morphinans. In particular, the invention provides methods for removing the N-substituent from the N-substituted morphinan to from a normorphinan carbamate, and then removing the carbamate functionality from the normorphinan carbamate to form the normorphinan.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: September 8, 2015
    Assignee: Mallinckrodt LLC
    Inventors: John Brandt, Subo Liao, Edmund C. Hudson, Esa T. Jarvi, Peter X. Wang, Michael Schaefer
  • PREPARATION OF NORMORPHINANS
    Publication number: 20150141649
    Abstract: The present invention provides processes for preparing normorphinans from N-substituted morphinans. In particular, the invention provides methods for removing the N-substituent from the N-substituted morphinan to from a normorphinan carbamate, and then removing the carbamate functionality from the normorphinan carbamate to form the normorphinan.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: John Brandt, Subo Liao, Edmund C. Hudson, Esa T. Jarvi, Peter X. Wang, Michael Schaefer
  • Processes for the alkylation of norbuprenorphine with reduced impurity formation
    Patent number: 8293906
    Abstract: The invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for the formation of buprenorphine and derivatives of buprenorphine that minimizes the formation of impurities.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: October 23, 2012
    Assignee: Mallinckrodt LLC
    Inventors: Esa T. Jarvi, James R. Meyer
  • Processes for the production of buprenorphine with reduced impurity formation
    Patent number: 8232397
    Abstract: The present invention provides process for the production of opiate alkaloids. In particular, the present invention provides processes for the production of buprenorphine or a derivative of buprenorphine that minimizes the formation of impurities.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: July 31, 2012
    Assignee: Mallinckrodt LLC
    Inventors: Brenda E. Allen, Esa T. Jarvi, Dennis J. Kalota, James R. Meyer, Keith G. Tomazi, Anthony Mannino, Brian Orr
  • N-Alkylation of Opiates
    Publication number: 20110269964
    Abstract: The present invention provides an efficient process for preparing N-alkylated opiates. In particular, processes are provided for using a chloride-containing alkylating agent and a bromide or iodide salt to alkylate the corresponding nor-opiate.
    Type: Application
    Filed: April 28, 2011
    Publication date: November 3, 2011
    Applicant: Mallinckrodt Inc.
    Inventors: Jian Bao, Catherine E. Thomasson, Esa T. Jarvi
  • Processes for the production of buprenorphine with reduced impurity formation
    Publication number: 20100087647
    Abstract: The present invention provides process for the production of opiate alkaloids. In particular, the present invention provides processes for the production of buprenorphine or a derivative of buprenorphine that minimizes the formation of impurities.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 8, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Brenda E. Allen, Esa T. Jarvi, Dennis J. Kalota, James R. Meyer, Keith G. Tomazi, Anthony Mannino, Brian Orr
  • Processes for the alkylation of norbuprenorphine with reduced impurity formation
    Publication number: 20100081820
    Abstract: The invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for the formation of buprenorphine and derivatives of buprenorphine that minimizes the formation of impurities.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 1, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Esa T. Jarvi, James R. Meyer
  • Synthesis of heteroaryl acetamides
    Patent number: 7385056
    Abstract: An improved process for the preparation of a heteroaryl acetamide from a heteroaryl ?-hydroxyacetamide is provied. The process comprises directly hydrogenating the heteroaryl ?-hydroxyacetamide in the presence of a strong acid, a halide and a catalyst. In one embodiment, the heteroaryl acetamide is zolpidem and the heteroaryl ?-hydroxyacetamide is ?-hydroxyzolpidem.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: June 10, 2008
    Assignee: Mallinckrodt Inc.
    Inventors: Esa T. Jarvi, Douglas C. Miller
  • Synthesis and purification of (r*,r*)-2-[ (dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride
    Patent number: 6399829
    Abstract: (R*,R*)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (Tramadol) is synthesized in a Grignard reaction in the presence of an additive resulting in a higher trans:cis ratio of product than is obtained in the absence of the additive. The Grignard reaction between 3 bromoanisole and the appropriate Mannich base in the presence of an amine or ether additive gives the amine product in an improved trans/cis ratio. The base is converted to its hydrochloride and recrystallized from a low molecular weight nitrile such as acetonitrile until a greater than 98% trans/cis ratio is obtained. Recrystallization from isopropanol gives (R*,R*)2-[(dimethylamino)methyl]-1-(3-metboxyphenyl)cyclohexanol hydrochloride free of the nitrile solvent. A hydrochloride of Tramadol can be synthesized without increasing a ratio of trans:cis by including a step in which HCl is added to Tramadol base in the presence of toluene.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: June 4, 2002
    Assignee: Mallinckrodt Inc.
    Inventors: Esa T. Jarvi, Neile A. Grayson, Robert E. Halvachs
  • Indole derivatives useful to treat estrogen-related neoplasms and disorders
    Patent number: 5877202
    Abstract: The present invention relates to novel indole derivatives useful in down-regulating estrogen receptor expression. Also included are methods for the treatment of neoplasms or of controlling the growth of a neoplasm in a patient afflicted with a neoplastic disease, especially estrogen-dependent neoplasms such as those associated with breast, ovarian and cervical tissue. Another embodiment of the present invention is a method of prophylactically treating a patient at risk of developing a neoplastic disease state. Also provided is a method for treating autoimmune diseases. Also included are pharmaceutical compositions of the novel indole derivatives.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: March 2, 1999
    Inventors: Alan J. Bitonti, Ian A. McDonald, Francesco G. Salituro, Jeffrey P. Whitten, Esa T. Jarvi, Paul S. Wright
  • Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
    Patent number: 5521162
    Abstract: This invention relates to certain aristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: May 28, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Esa T. Jarvi, James R. McCarthy, Nellikunja J. Prakash
  • 5'-vinylhalo-aristeromycin/adenosine analogs and immunosuppressants
    Patent number: 5470837
    Abstract: The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-vinylhalo-aristeromycin/adenosine analogs.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: November 28, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey A. Wolos, Niall S. Doherty, Esa T. Jarvi, James R. McCarthy
  • Process for the preparation of di-fluro analogs of squalene
    Patent number: 5157166
    Abstract: This invention relates to a process for making di-fluoro analogs of squalene.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: October 20, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Esa T. Jarvi, Michael L. Edwards, James R. McCarthy
  • Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
    Patent number: 5064864
    Abstract: This invention relates to certain novel di- and tetra-fluoro analogs of squalene and to their methods of use in lowering plasma cholesterol and in inhibiting squalene epoxidase in patients in need thereof.
    Type: Grant
    Filed: December 12, 1990
    Date of Patent: November 12, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Esa T. Jarvi, Michael L. Edwards, James R. McCarthy
  • Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
    Patent number: 5011859
    Abstract: This invention relates to certain novel di- and tetra-fluoro analogs of squalene and to their methods of use in lowering plasma cholesterol and in inhibiting squalene epoxidase in patients in need thereof.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: April 30, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Esa T. Jarvi, Michael L. Edwards, James R. McCarthy
  • 5'-deoxy-4',5'-unsaturated-5'-substituted adenosines
    Patent number: 4997924
    Abstract: This invention relates to certain aristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Grant
    Filed: November 29, 1989
    Date of Patent: March 5, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Esa T. Jarvi, James R. McCarthy, Nellikunja J. Prakash
  • 5'-deoxy-5',5'-dihalo adenosines and purine analogues
    Patent number: 4997925
    Abstract: This invention relates to certain 5',5'-dihaloaristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Grant
    Filed: July 14, 1989
    Date of Patent: March 5, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Esa T. Jarvi, James R. McCarthy, Mellikunja J. Prakash